Adaptive Biotechnologies Corporation ADPT
29.94 USD +0.58 (+1.98%)
At closeNov 12, 2026, 4:01 AM EST
29.78 -0.16 -0.53%
Pre-market · Nov 12, 4:01 AM ET
29.83 Day range 32.13
12.00 52-week range 32.13
- YTD
- +84.36%
- 1 year
- +106.06%
News
globenewswire.com Adaptive Biotechnologies to Participate in Upcoming Investor Conferences SEATTLE, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), ), a commercial stage biotechnology company that aims to translate the…
zacks.com Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run? Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
benzinga.com Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34 Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $32 to $34.
defenseworld.net Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Has Average Target Price of $30.06 Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight research firms that are currently covering the firm,…
benzinga.com Adaptive Biotechnologies Q3 2026 Earnings Call Transcript Adaptive Biotechnologies (NASDAQ:ADPT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com MercadoLibre, Banco Bradesco, Itaú Unibanco And Other Big Stocks Moving Lower In Monday’s Pre-Market Session Brazilian stocks plunged premarket after Lula's reelection, led by XP (-46%), Inter & Co (-34.7%), StoneCo (-33.8%) and MercadoLibre (-14.1%).
benzinga.com TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32 TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $28 to $32.- benzinga.com Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $27 Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $22 to $27.